Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Cantor Fitzgerald Maintains Neutral on Regeneron Pharmaceuticals, Raises Price Target to $1000

Author: Benzinga Newsdesk | July 22, 2024 11:33am
Cantor Fitzgerald analyst Olivia Brayer maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Neutral and raises the price target from $925 to $1000.

Posted In: REGN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist